Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ICMT | O60725 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | ADH1C | P00326 | 1/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.41 |
| ▸ | ADH4 | P08319 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16415141 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL16415177 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL3458582 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL1685969 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL707050 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL16414653 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL704307 | 0.98 | NPC1 (0.49) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL489809 | 0.92 | TDP1 (0.46) | NPC1JAK2RAB9APAX8KCNH2 | |
| Chloromethane SCHEMBL7281088 | 0.89 | NPC1 (0.44) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL709444 | 0.84 | TP53 (0.44) | NPC1JAK2RAB9APAX8TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6337176-B1 | COLOR REPRODUCTION AND SHARPNESS; RAPID PROCESSING | FUJI PHOTO FILM CO., LTD. (JP) | 2002-01-08 | — | — | US | claimed |
| EP-2841433-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL CO (JP) | 2017-06-21 | — | — | EP | disclosed |
| US-9380782-B2 | Tetrazolinone compounds and its use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-05 | — | — | US | disclosed |
| EP-2841433-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | Sumitomo Chemical Company Limited (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20150031733-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| WO-2013162077-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-10-31 | — | — | WO | disclosed |
| US-6337176-B1 | COLOR REPRODUCTION AND SHARPNESS; RAPID PROCESSING | FUJI PHOTO FILM CO., LTD. (JP) | 2002-01-08 | — | — | US | disclosed |
| US-5728514-A | Silver halide color photographic material and method for forming color image | FUJI PHOTO FILM CO, LTD. (JP) | 1998-03-17 | — | — | US | disclosed |
| EP-0317983-B1 | Silver halide color photographic material | FUJI PHOTO FILM CO LTD (JP) | 1994-06-01 | — | — | EP | disclosed |
| US-5100771-A | SILVER HALIDE COLOR PHOTOGRAPHIC MATERIAL WITH WATER INSOLUBLE ORGANIC SOLVENT SOLUBLE POLYMER | FUJI PHOTO FILM CO., LTD. (JP) | 1992-03-31 | — | — | US | disclosed |
| EP-0317983-A2 | Silver halide color photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031733-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | CBR3, CYP51A1, CYP8B1 | NPC1 2859/4885JAK2 1162/4885RAB9A 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.